Epirus Biopharmaceuticals Inc  

(Public, NASDAQ:EPRS)   Watch this stock  
Find more results for MALLINCKRODT, INC
-0.04 (-0.84%)
Dec 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.70 - 4.83
52 week 3.78 - 22.50
Open 4.78
Vol / Avg. 28,035.00/27,535.00
Mkt cap 62.09M
P/E     -
Div/yield     -
EPS -4.84
Shares 12.93M
Beta 1.52
Inst. own 57%
Mar 11, 2015
Q4 2014 Epirus Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Nov 10, 2014
Q3 2014 EPIRUS Biopharmaceuticals Inc Earnings Release
Sep 26, 2014
Epirus Biopharmaceuticals Inc at BioCentury Publications NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -262.15%
Operating margin - -252.60%
EBITD margin - -172.63%
Return on average assets -158.53% -113.30%
Return on average equity -197.12% -
Employees 27 -
CDP Score - -


699 Boylston St Fl 11
BOSTON, MA 02116-2848
United States - Map
+1-617-6004164 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


EPIRUS Biopharmaceuticals Inc, formerly Zalicus Inc, is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. It focuses on the discovery and development of selective ion channel modulators and its combination high throughput screening technology (cHTSTM) to discover new product candidates for its portfolio or for its collaborators in the areas of pain, inflammation, oncology and infectious disease. In July 2014, EPIRUS Biopharmaceuticals Inc announced that it has completed the merger with Zalicus Inc.

Officers and directors

Amit Munshi President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Thomas Shea Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
J. Kevin Buchi Director
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Geoffrey M. Duyk M.D., Ph.D. Director
Age: 54
Bio & Compensation  - Reuters
Daotian Fu Director
Bio & Compensation  - Reuters
Julie McHugh Director
Bio & Compensation  - Reuters